blog

2021: A Look Inside Our Crystal Ball (part one)

By Elizabeth Gargill on Mon, Dec 21, 2020 | 5 min read

 

As part of our Crystal Ball series, we asked BBK Worldwide President Matt Kibby to comment on the clinical research landscape and to share his predictions for 2021.

Matt Kibby, Principal, President

Is there a particular trend that you expect to have a significant impact on the industry in the coming year?

 

With COVID-19 dominating the headlines for much of 2020, one might expect that a key development for clinical R&D in 2021 will be the continued integration and expansion of services that support the hybridization / decentralization of clinical trials. Keeping trial participants – who tend to be older and at greater risk for complications from COVID-19 – away from clinical trial sites not only reduces the risk of SARS-COV-2 infection, but also offers the possibility of enrichment of the clinical trial experience; reduces the overall visit and expense burden for patients; and, moreover, reduces the trial burden on clinical trial site healthcare professionals.

Topics: BBK Worldwide, Patient Engagement, Patient Travel, Patient Experience, Patient Enrollment, Matt Kibby, Clinical Trial Patient Travel, 2021 Predictions, 2021, Underserved Populations

Survey Reveals Site Perspectives on Clinical Trial Services

By Elizabeth Gargill on Tue, Dec 1, 2020 | 2 min read

What do doctors and nurses think about solutions designed to make clinical trials easier to conduct? Are they helpful? Do they alleviate burdens? And which ones do they prefer?

In this special Pharma15 Live! segment, BBK Worldwide industry experts Matt Kibby and Aaron Fleishman discuss recent Study Voices survey results that shed light on this topic. They examine doctor and nurse perspectives on services designed to provide support in conducting clinical trials — including services for virtual, hybrid, and decentralized clinical trials.

“We were looking at whether or not doctors and nurses at sites that were conducting clinical trials would appreciate different types of services that assist with their ability to conduct them."

-Matt Kibby, Principal, President, BBK Worldwide

Topics: Clinical Trials, Pharma15 Live!, Study Voices, COVID-19, Matt Kibby, Aaron Fleishman, Decentralized Trials, Virtual, Study Voices 2020, Surveys, Site Voice, Hybrid Trials

Pharma15 Live! Director’s Chair

By Aaron Fleishman on Fri, Jul 17, 2020 | 3 min read

 

As the director and one of the producers of Pharma15 Live! I wanted to share with you some insights into what we’ve learned through an amazing three seasons! First of all, if you were to tell me at the beginning of our series that it would even last three seasons, I’d tell you I’d be shocked – but nonetheless here we are and it’s been great!

Topics: Pharma15 Live!, COVID-19, Matt Kibby, Aaron Fleishman, Craig Lipset, Advarra, Season Three, Michele Russell-Einhorn, Dan Sfera, Ray Dorsey, MD

The Impact of COVID-19 on Clinical Trials: Where Are We? And Where Are We Going?

By Aaron Fleishman, Director, Market Development on Tue, Jun 23, 2020 | 2 min read

As the country goes through the phases of reopening, what does that mean for the patient and site experience in clinical trials? PharmaTalkRadio’s Valerie Bowling discusses the future of clinical trials with Ray Dorsey, MD, Matt Kibby, and Craig Lipset in this feature podcast.

Topics: Clinical Trials, Pharma15 Live!, COVID-19, Matt Kibby, Craig Lipset, Decentralized Trials, Conference Forum

Maintaining Clinical Trial Momentum during COVID-19 and Beyond

By Elizabeth Gargill on Thu, Apr 23, 2020 | 1 min read

In our latest Pharma15 Live! COVID-19 special report, BBK's President Matt Kibby introduces a new framework for helping clinical trial sponsors maintain study momentum during COVID-19 and beyond.

The framework features strategies for minimizing disruption during four key stages of the study lifecycle.

Topics: Patient Engagement, Pharma15 Live!, Patient Enrollment, COVID-19, Coronavirus, Matt Kibby

 
Subscribe To Our Blog